Abstract
The use of cell-based therapy may be a valid therapeutic approach to ischemic brain injury. Stem cells have been proposed as a new form of cell based therapy in a variety of disorders, including acute and degenerative brain diseases. Up to date most efforts have concentrated on transplantation of embryonic stem cells (ESC) or neural stem cells (NSCs) obtained from immortalized cell lines into the diseased brain. These procedures require harvesting the appropriate stem cell, expansion in vitro and transplantation. Endogenous NSCs have been identified in the central nervous system where they reside largely in the subventricular zone and in the subgranular zone of the hippocampus. Endogenous NSCs may be capable of self-renewal and differentiation into functional glia and neurons. Manipulation of endogenous NSCs may bypass the need to use ESC as a form of therapy thus avoiding the complex ethical and biological issues involved with ES cells or immortalized cell lines. This review summarizes the evidence recently gathered in support of a therapeutic role for endogenous NSCs in acute experimental stroke.
Keywords: neural stem cells, neurogenesis, stroke, ischemia, growth-factors
Current Neurovascular Research
Title: Using Endogenous Neural Stem Cells to Enhance Recovery from Ischemic Brain Injury
Volume: 1 Issue: 5
Author(s): Ronen R. Leker and R. D.G. McKay
Affiliation:
Keywords: neural stem cells, neurogenesis, stroke, ischemia, growth-factors
Abstract: The use of cell-based therapy may be a valid therapeutic approach to ischemic brain injury. Stem cells have been proposed as a new form of cell based therapy in a variety of disorders, including acute and degenerative brain diseases. Up to date most efforts have concentrated on transplantation of embryonic stem cells (ESC) or neural stem cells (NSCs) obtained from immortalized cell lines into the diseased brain. These procedures require harvesting the appropriate stem cell, expansion in vitro and transplantation. Endogenous NSCs have been identified in the central nervous system where they reside largely in the subventricular zone and in the subgranular zone of the hippocampus. Endogenous NSCs may be capable of self-renewal and differentiation into functional glia and neurons. Manipulation of endogenous NSCs may bypass the need to use ESC as a form of therapy thus avoiding the complex ethical and biological issues involved with ES cells or immortalized cell lines. This review summarizes the evidence recently gathered in support of a therapeutic role for endogenous NSCs in acute experimental stroke.
Export Options
About this article
Cite this article as:
Leker R. Ronen and McKay D.G. R., Using Endogenous Neural Stem Cells to Enhance Recovery from Ischemic Brain Injury, Current Neurovascular Research 2004; 1 (5) . https://dx.doi.org/10.2174/1567202043361938
DOI https://dx.doi.org/10.2174/1567202043361938 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer
Current Medical Imaging MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews The Central Role of Leukotriene B4 in Epstein Barr Virus Activated Innate Immunity In Vitro
Current Immunology Reviews (Discontinued) T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Preface
Current Drug Targets - CNS & Neurological Disorders Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design The HAG Mechanism: A Molecular Rationale For The Therapeutic Application Of Iron Chelators In Human Diseases Involving the 2-Oxoacid Utilizing Dioxygenases
Current Medicinal Chemistry Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences
Current Drug Delivery Opioid-induced Cardioprotection
Current Pharmaceutical Design Peptide Mediated Brain Delivery of Nano- and Submicroparticles: A Synergistic Approach
Current Pharmaceutical Design Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry